Aptose Biosciences Inc. 8-K

What Happened
Aptose Biosciences Inc. (APTOF) filed a Form 8-K reporting the results of its Special Meeting held on March 31, 2026. Shareholders voted to (1) approve continuation of the company from the Canada Business Corporations Act (CBCA) to the Business Corporations Act (Alberta), and (2) approve a plan of arrangement under which HS North America Ltd., a wholly owned subsidiary of Hanmi Pharmaceutical Co. Ltd., will acquire all Aptose common shares not already owned or controlled by the Hanmi purchasers or their affiliates. The arrangement had been previously announced on November 19, 2025 and February 24, 2026.

Key Details

• Meeting date: March 31, 2026.
• Continuance Resolution (Proposal 1): For 1,075,838 votes (92.42%), Against 76,950 (6.61%), Abstain 11,242.
• Arrangement Resolution (Proposal 2): For 556,154 votes (84.87%), Against 97,552 (14.89%), Abstain 1,614.
• Purchaser: HS North America Ltd., wholly owned by Hanmi Pharmaceutical Co. Ltd.

Why It Matters
These shareholder approvals are material steps in completing the proposed acquisition by Hanmi. The continuance to Alberta law changes the company’s governing statute and is typically done to align corporate governance with the transaction steps. Approval of the arrangement indicates shareholder support to proceed with the acquisition process; next steps will be completion of any remaining conditions set out in the arrangement and any required regulatory approvals before closing.